MAPT and dementia: In the absence of translational experimental post-ischemic therapies in animals for clinical use [61], the emphasis is on reducing the neurotoxic effects of amyloid and tau protein on post-ischemic neurons to prevent brain neurodegeneration with dementia of Alzheimer’s disease-type.